11
Albert Louis Anna Willemsens, Walter Louis Antoine Verstappen, Alex Herman Copmans, Anna Maria Jozefa Vandendriessche, Alfons Gaston Maria De Knaep, Marc Gaston Venet: Process for preparing enantiomerically pure 6-{4-chlorophenyl) (1 H-1,2,4-triazol-1-YL) methyl}-1-methyl-1 H-benzotriazole. Janssen Pharmaceutica, Ellen Ciambrone Coletti, May 5, 1998: US05746840 (1 worldwide citation)

A process for preparing (+)-6-�(4-chlorophenyl)(1H- 1,2,4-triazol-1-yl)methyl!-1-methyl-1H-benzotriazole comprising the resolution of (.+-.)-6-!(4-chlorophenyl)-hydrazinomethyl)-1-methyl-1H-benzotriazole and converting the appropriate enantiomerically pure hydrazine intermediate into (+)-6-�(4-chlor ...


12
Albert Louis Anna Willemsens, Walter Louis Antoine Verstappen, Alex Herman Copmans, Anna Maria Jozefa Vandendriessche, Alfons Gaston Maria De Knaep, Marc Gaston Venet: Process for preparing enantiomerically pure 6-[(4-chlorophenyl) (1H-1,2,4-triazol-1-yl) methyl]-1-methyl-1H-benzotrizole. Janssen Pharmaceutica, Charles J Metz, September 2, 1997: US05663354 (1 worldwide citation)

A process for preparing (+)-6-[(4-chlorophenyl)(1H-1,2,4-triazol-1-yl)methyl]-1-methyl-1H-benzotri azole comprising the resolution of (.+-.)-6-[(4-chlorophenyl)-hydrazinomethyl)-1-methyl-1H-benzotriazole and converting the appropriate enantiomerically pure hydrazine intermediate into (+)-6-[(4-chlor ...


13
Rudy Laurent Maria Broeckx, Walter Ferdinand Maria Filliers, Patrick Hubert J Nieste, Alex Herman Copmans, Filip Marcel Vanhoutte, Carina Leys: Crystalline 6-(2-((4-amino-3-(3-hydroxyphenyl)-1H-pyrazolo[3,4-D]pyrimidin-1-yl)methyl)-3-(2-chlorobenzyl)-4-0X0-3,4-dihydroquinazolin-5-yl)-N,N-bis(2-methoxyethyl)hex-5-ynamide. Respivert, Ada O Wong, May 9, 2017: US09642799

There is provided inter alia 6-(2-((4-amino-3-(3-hydroxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl) methyl)-3-(2-chlorobenzyl)-4-oxo-3,4-dihydroquinazolin-5-yl)-N,N-bis(2-methoxyethyl)hex-5-ynamide in the form of a solid crystalline hydrate and in solid crystalline anhydrous form. There are also provi ...


14
David Michel Adrien Taddei, Stuart Thomas Onions, Alun John Smith, Alex Herman Copmans, Rudy Laurent Maria Broeckx: Phosphoinositide 3-kinase inhibitors. Respivert, Bradley E Davis, January 5, 2016: US09227977

The present invention relates inter alia to a compound of formula (I) and to compositions comprising the same and to the use of the compounds and to compositions of the compounds in treatment, for example in the treatment of inflammatory diseases, in particular respiratory inflammatory disease. The ...


15
Alex Herman Copmans, Jérôme Albert Joseph Hoet, Albert Louis Anna Willemsens, Wouter Louis J Couck, Joannes Petrus Van Dun: Resolution of (±)-methyl phenyl[4-[4-[[[4′(trifluoromethyl)-2-biphenylyl]carbonyl]amino]Phenyl]-1-piperidinyl]acetate. Janssen Pharmaceutica, June 11, 2013: US08461341

The present invention relates to a resolution process of (±)-methyl phenyl[4-[4-[[[4′-(trifluoromethyl)-2-biphenylyl]carbonyl]amino]phenyl]-1-piperidinyl]acetate to isolate the MTP (microsomal triglyceride transfer protein) inhibitor methyl (2S)-phenyl[4-[4-[[[4′-(trifluoromethyl)-2-biphenylyl]carbo ...


16

17
Stevens Paul Theodoor Agnes, Peeters Jozef, Vandecruys Roger Petrus Gerebern, Stappers Alfred Elisabeth, Copmans Alex Herman: Chlorhydrate de 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethyl-phenyl]amino]-2-pyrimidinyl]amino]benzonitrile, Hydrochloride of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile. Janssen Pharmaceutica, Janssen Pharmaceutica, Gowling Lafleur Henderson, November 30, 2010: CA2577288

The present invention relates to a pharmaceutical composition comprising as active ingredient the hydrochloric acid salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethyl- phenyl]amino]-2-pyrimidinyl]amino]benzonitrile and to processes for their preparation.


18

19

20
Jerome Emile Georges Guillemont, Paul Theodoor Agnes Stevens, Alex Herman Copmans, Jozef Peeters, Alfred Elisabeth Stappers, Roger Petrus Gerebern Vandecruys, Paul Stoffels: Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile. Philip S Johnson, Johnson & Johnson, May 25, 2006: US20060111379-A1

The present invention relates to a pharmaceutical composition comprising as active ingredient the hydrochloric acid salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile and to processes for their preparation.